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Communication about the risks of medicines is
not a new issue. Patients have long since sought
advice about remedies, whether from family,
healthcare workers or the wider community in
traditional ways, or via websites and social media
in today’s world. As pharmacovigilance profes-
sionals, interacting with patients, healthcare pro-
fessionals, health policy makers, journalists and
the general public has become part of our daily
activity, in order to manage risks with medicines
appropriately and reduce patient harm.
So why is this theme edition of Drug Safety
focusing on risk communication now? A decade
ago, risk management was introduced into
pharmacovigilance,[1] and the implementation and
evaluation of this approach are still subject to
improvement in the light of experience gained so
far. But it has become clear that at the core of
successful risk management lies effective risk com-
munication. This applies to formal risk manage-
ment plans as well as to risk minimization action
otherwise taken for a medicine and interactions
between healthcare professionals and patients.
Drug Safety has increasingly been a forum for dis-
cussing risk communication,[2-11] and given that
applying communication science to pharma-
covigilance is relatively new, we thank the journal
editors for now dedicating a whole edition to this
topic.
Articles were invited from authors with dif-
ferent kinds of relevant expertise and with a view
to covering perspectives from various stake-
holders and world regions. The resulting con-
tributions include original research, reviews and
opinion papers. It is perhaps not surprising – due
to the still limited research – that often opinions
are underpinned by experiences rather than
systematic evidence, and this illustrates the need
for further research. There is now an urgent need
to look at old and new ideas for risk commu-
nication under a magnifying glass, in order to
explore how to put established principles into
practice and to experiment with new approaches.
Why is this urgent? Avoidable adverse reac-
tions and medication errors are still a leading
cause for morbidity andmortality,[12-21] and there
are ongoing patient needs for information to fa-
cilitate treatment choices.[22]
In their article on patients’ expectations, Cox
and Butt[23] remind us of the need for information
about benefits as well as risks and that prescribers
may prefer to highlight benefits rather than risks
of medicines. Referring to their own research,
they stress that patients often lack under-
standable risk information and want their nega-
tive experiences to be taken seriously. This is
described as fundamental for the trust of patients
in their healthcare professionals and treatments.
Furthermore, the authors discuss that differences
in risk perceptions between patients and health-
care professionals may be a barrier to one-to-one
communication.
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This barrier also exists when communicatingwith
broader audiences, andDodoo andHugman[24] give
us important advice in this respect: public con-
cerns have to be addressed, whether or not, as
pharmacovigilance professionals, we share these
concerns. The authors take us on a journey through
sub-Saharan Africa, with examples illustrating how
risk communication may be linked with social
problems and citizens’ trust – or often mistrust – in
governments. We should hence understand that we
cannot look at a safety concern in isolation, but
that the social and political context should be con-
sidered for every communication intervention
about a medicine with public health relevance.
Every time communication fails, public trust in
medicines is eroded and this trust is difficult to
re-build. This may result in using medicines in-
appropriately or avoiding them altogether, which
could threaten patient and public health. The need
to establish trust in pharmacovigilance systems at
both individual and population level adds to the
urgency of this theme edition.
Similar lessons can be learnt from the Philippines,
and Hartigan-Go[25] advises us to keep ourselves
on a constant learning curve, as past experiences
should inform future communication strategies.
He advocates that risk management and com-
munication should become an accepted culture
within governments, healthcare and pharmaceu-
tical industry, and recommends applying the
social marketing approach for promoting safe
use of medicines. Among the many challenges
he describes as prevalent in the developing world
is also the difficulty for healthcare professionals
to keep aware of all latest evidence.
This is not easy elsewhere either, as reported
from the Netherlands by Piening et al.[26] By
means of a survey, they further found that the
majority of Dutch healthcare professionals con-
sidered receiving risk communication important
and that almost one-third reported taking action
following a direct healthcare professional com-
munication (DHPC). This might be considered a
disappointing figure, but in some other areas
achieving a behavioural impact by a single act of
communication in one-third of the targeted au-
dience would be a success. The authors suggest a
mix of tools for disseminating information to
impact on more healthcare professionals, as
necessary for patient safety. This kind of research
into healthcare professional and other audiences
is much needed and we hope to see more in other
countries too. We will also need objective mea-
surements of behaviour, rather than relying on
self-reported impact. The impact crucially de-
pends on the trust in the information source, and
Piening et al.[26] found that healthcare profes-
sionals prefer to be informed by governmental or
their own professional bodies, and not by phar-
maceutical industry.
Edwards and Chakraborty[27] discuss commu-
nication frommanufacturers, including public mis-
trust. They highlight that improvements through
proper effectiveness evaluation of communication
remains to be achieved and suggest learning from
patient information leaflets, which have been im-
proved much through testing. For manufacturers’
communication strategies, the authors recommend
coherent strategies across the organization and
agreeing the strategy’s objectives with the regula-
tory authority. But they also conclude that common
understanding between manufacturers and reg-
ulators is often lacking, as to whether risk commu-
nication intends to inform, to help understanding or
to change behaviour of medicine users. So working
together towards a common understanding is fun-
damental for future progress.
How regulators can gain clarity on their com-
munication objectives can be learnt from the arti-
cle by Fischhoff.[28] He proposes a framework for
decision making on the benefit-risk balance of
medicines, which both requires and facilitates
communication. The framework integrates calcu-
lations and statistics with judgement on the quality
and strength of the evidence, based on transpar-
ently agreed values and criteria. Methodological
clarity should facilitate communication between
experts, decision makers and other stakeholders,
with a view to explaining to the public why a cer-
tain decision was taken. This honesty about value-
based judgements upon the evidence may enable
us, as pharmacovigilance experts, to communicate
effectively in the given social and political contexts.
These contexts have been studied for vaccines
more than for most other medicines, and Larson
et al.[29] give us proof of many points discussed in
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other articles in this theme edition, with major
examples for vaccines. Again, there is advocacy
for an integrated approach of risk assessment,
minimization and communication, also integrating
the monitoring of public concerns. The authors
make other very important points: listening must
be part of communication, and rather than sticking
to standard messages that have not worked in
certain circumstances, messages should be tailored
to respect each community, address their specific
concerns and gain their trust. This approach could
increase vaccine acceptance, and given the ex-
amples of (re)occurrence of vaccine-preventable
disease outbreaks, this is another urgent call.
While we may realize that we need to urgently
improve risk communication, we should also un-
derstand that to make that happen a fundamental
shift is needed in the way we work as pharma-
covigilance professionals, in whichever setting.
To help us in making that shift, Hugman[30]
whirls us across countries, backwards and for-
wards in time and through fiction and non-fiction.
While appreciating the principles of democratic
public administrations to provide services to the
public based on equality and fairness, he warns us
of obstacles administrations can create with ne-
gative impact on communication. He applies his
criticism of bureaucracies not only to public ad-
ministrations, but also to those in healthcare and
pharmaceutical industry. In order to overcome
rigidmindsets, he draws our eyes to compassionate
problem solving through ‘creative bureaucracies’
which are honest, ethical, efficient, motivating,
non-hierarchical, networking, interdisciplinary,
multicultural and, of course, patient-centred! Ulti-
mately, Hugman[30] gives us the lens for our focus
in pharmacovigilance in general and communica-
tion in particular: how can we ensure that every-
thing we do contributes to patient safety and
welfare?
Applying this lens to the integration of risk
assessment, minimization and communication
and decision making upon the benefit-risk bal-
ance of a medicine, shows us that an integrating
framework should not add procedural obstacles,
but facilitate problem solving.
We also agree that this should result in com-
munication interventions tailored for specific
audiences and that ‘not one size fits all’, as dis-
cussed in articles in this theme edition. However,
we face a dilemma when we have to communicate
with broad audiences as regards how far we can
tailor messages without appearing to issue in-
consistent messages. Also, since communication
needs and preferences differ by many factors, we
should reflect upon the need for, but also the
feasibility of, audience segment-specific data
versus the generalizability of less segmented data.
Furthermore, we must consider that patients
and healthcare professionals may already be con-
fused by different information sources, as some
authors highlight. Team effort, in particular with
listening to patients and working with patient or-
ganizations, is therefore required from as many
stakeholders as possible to get agreement on mes-
sages. Embracing our world of plurality, we need to
strengthen our communication practices in order to
make our voice heard in the interest of patients.
Where should we focus now in order to pro-
gress? Not all ideas presented in this theme edition
are new – most importantly we should remember
the Erice Report[31] and its recent update enforcing
patients’ interests[32] – but implementation is not
so easy.While progress has been achieved in some
areas, other established principles of good com-
munication practices are not yet systematically
followed. Also, the communication environment
has seen rapid changes recently in terms of social
and political contexts, such as increased public
demands for information, as well as significant
developments in information technology and re-
lated communication behaviour. This theme edi-
tion reflects upon the challenges these changes
present, and we are grateful to the authors for in-
spiring us with new ideas on how to tackle these.
Ultimately, the usefulness of all our efforts in
pharmacovigilance will manifest itself in our ability
to communicate practical advice for the safe use of
medicines. This advice should achieve improved
patient health outcomes. This is a high goal, but we
cannot settle for less. Inadequate communication is
a risk in itself, and hence communication expertise
and functions within pharmacovigilance should be
installed alongside all other crucial functions. Let’s
focus on this now – the safety of patients will de-
pend on it.
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